Irbesartan
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Irbesartan: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Irbesartan is an angiotensin II receptor blocker (ARB) whose established pharmacology centers on treating hypertension by blocking the AT1 receptor and suppressing RAAS activity. The TxGNN model predicts a possible new application in Malignant Hypertensive Renal Disease, but this prediction is currently supported by 0 clinical trials and 0 publications, making it a pure model-level hypothesis at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (based on irbesartan's known ARB classification; not explicitly captured in this Evidence Pack's original_indications field) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action data from DrugBank is currently a data gap (DG002) in this Evidence Pack. Based on the mechanistic rationale accompanying the prediction, irbesartan is an AT1 receptor antagonist (ARB) that lowers intraglomerular pressure and reduces proteinuria by blocking angiotensin II activity — a mechanism with an established pharmacological basis in general hypertensive nephropathy (e.g., diabetic nephropathy).
However, malignant hypertensive renal disease is an acute, emergent condition requiring rapid blood pressure control alongside often precipitous renal function deterioration. ARBs have a relatively slow onset of action, and in the setting of acutely worsening renal function, RAAS blockade carries risk of hyperkalemia and further GFR decline. The TxGNN score therefore appears to reflect a general RAAS-pathway association rather than a validated clinical opportunity, and — notably — the accompanying rationale for related predictions (e.g., malignant renovascular hypertension) explicitly flags ARB use in this context as a potential safety concern rather than a therapeutic signal, since ARB/ACEi blockade of the compensatory efferent arteriolar constriction in renovascular disease can precipitate acute renal failure.
Given the complete absence of clinical trials or literature specifically evaluating irbesartan in this indication, this prediction should be interpreted as a pathway-level hypothesis generated by the model, not as evidence of therapeutic benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Irbesartan is currently not marketed in Taiwan (0 marketing authorizations on record). No license or product-level data is available in this Evidence Pack.
Safety Considerations
Please refer to the package insert for safety information. A blocking data gap (DG001) has been identified: TFDA package insert warnings/contraindications have not yet been retrieved, which prevents entry into the S1 safety pre-assessment stage. No drug-drug interaction records were found (query_status: not_found).
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication carries only L5 (model-prediction-only) evidence with zero supporting clinical trials or literature, the drug is not currently marketed in Taiwan, and a blocking safety data gap (TFDA labeling) prevents any formal safety pre-assessment. Additionally, the mechanistic rationale itself raises caution rather than confidence, given known risks of RAAS blockade in acute/renovascular renal compromise.
To proceed, the following is needed:
- Retrieve TFDA package insert (warnings, contraindications) to resolve blocking data gap DG001
- Confirm formal DrugBank MOA record to resolve data gap DG002
- Targeted literature/clinical trial search specifically on irbesartan (or ARB class) in malignant hypertensive renal disease and renovascular hypertension populations
- Renal function and potassium monitoring protocol, given the mechanistic risk of RAAS blockade in acute renal compromise
- Route compatibility assessment (currently marked "pending" in the Evidence Pack)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.